基亞生物科技股份有限公司 Approved
最後更新時間 2025/06/03 , 08:21 AM
最後更新時間 2025/06/03 , 08:21 AM
負責人
Zhang,Shi-Zhong
統一編號
70760897
成立日期
1999/12/31
資本額
NT$2,500,000,000
實收資本額
NT$1,392,297,550
股票代號
3176
電話
02-26535200
地址
14F, No. 3, Park St., Nangang Dist., Taipei City, 115, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Zhang,Shi-Zhong Chairman 1.29%
Zhang,Zi-Ling Director 10.18% EVERSPRING INDUSTRY CO., LTD.
Huang,Zi-Liang Director 1.74% HUA CHEN SECURITY CO., LTD.
Zhuang,Ming-Li Director 3.14% DA QING CONSTRUCTION CO., LTD.
Zhuang,Xiu-Ming Independent Director 0.00%
Wang,Zhu-Ke Independent Director 0.00%
Chen,Bei-Wei Independent Director 0.00%
Lin,Xue-Rong Independent Director 0.00%
營業項目
  • Wholesale of Pharmaceutical and Medical Goods(457112)
  • Medical Test and Examination Activities(869100)
  • Other Professional, Scientific and Technical Activities Not Elsewhere Classified(760999)
  • 公司歷程
  • Change Capital to 2,500,000,000
    2019/06/25
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 499,372 1,372,701 1,157,720
    Operating cost 144,290 618,944 540,391
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 355,082 753,757 617,329
    Unrealized profit (loss) on sales of goods 51,126 - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 303,956 753,757 617,329
    Operating expenses 206,122 970,952 1,850,422
    Other gain (loss), net - - -
    Operating profit (loss) 97,834 -217,195 -1,233,093
    Non-operating income and expenses 6,688 104,479 -45,767
    Net profit (loss) before tax 104,522 -112,716 -1,278,860
    Income tax expense (benefits) 7,493 109,673 191,207
    Net profit (loss) of ongoing business for the current period 97,029 -222,389 -1,470,067
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period 97,029 -222,389 -1,470,067
    Other comprehensive profit (loss), net -76,392 85,867 16,038
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period 20,637 -136,522 -1,454,029
    Net profit (loss) attributable to owners of parent company 102,450 -204,690 -561,296
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests -5,421 -17,699 -908,771
    Comprehensive profit (loss) attributable to owners of parent company 74,771 -174,729 -554,889
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests -54,134 38,207 -899,140
    Basic earnings per share (yuan) 0 -1 -4
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -28,958 37,919 -503,517
    Net cash inflows (outflows) from investing activities -374,749 903,302 497,660
    Net cash inflow (outflow) from financing activities -6,494 -1,773,172 193,152
    Effect of Exchange Rate Changes on Cash and Cash Equivalents -707 -3,262 -5,002
    Increase (decrease) in cash and cash equivalents in the current period -410,908 -835,213 182,293
    Beginning balance of cash and cash equivalents 1,387,713 2,222,926 2,040,633
    Ending balance of cash and cash equivalents 976,805 1,387,713 2,222,926
    項目 2025 2024 2023
    Current asset 3,709,505 3,661,148 5,708,037
    Non-current asset 2,908,549 3,049,345 2,819,208
    Total asset 6,618,054 6,710,493 8,527,245
    Current liability 790,840 925,220 2,779,891
    Non-current liability 731,733 747,214 750,225
    Total liability 1,522,573 1,672,434 3,530,116
    share capital 1,393,068 1,393,068 1,394,748
    Equity - secruity token - - -
    capital reserve 566,460 536,791 968,142
    retained earning -250,212 -352,662 -747,509
    Other equity -22,986 4,693 -23,738
    Treasury stock - - -
    Total equity attributable to owners of parent company 1,686,330 1,581,890 1,591,643
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests 3,409,151 3,456,169 3,405,486
    Total Equity 5,095,481 5,038,059 4,997,129
    Share capital awaiting retirement (unit: share) - 0 200,000
    Issued shares of advance equity (unit: shares) 0 0 83,500
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 12 11 11
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額 0
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額 0
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    2024 01-04 0M 0~0.5M
    2023 01-12 0~0.5M 0~0.5M
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    商標
  • Magicell
  • Cellxpert
  • Clolyse
  • 基亞MEDIGEN
  • 基亞生物科技股份有限公司標章
  • 基亞 MEDIGEN
  • 專利
  • 整合性自動化細胞培養裝置
  • 整合性自動化細胞培養裝置
  • 整合性自動化細胞培養裝置
  • 用於體外擴增暨活化自然殺手細胞之細胞培養基
  • 自動化細胞培養裝置
  • 體外擴增暨活化自然殺手細胞之方法及其醫藥組合物
  • 自動化細胞培養裝置
  • 硫化寡醣在製備治療手術後肝細胞癌病患之藥物的用途
  • 硫化寡醣衍生物用於抑制肝癌復發、惡化或轉移之用途
  • 熱對流聚合酶連鎖反應之方法及裝置
  • 政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    HLA-B27定型試劑套組單價合約 國立臺灣大學醫學院附設醫院 106/04/25 276480.0
    HLA-B27定型試劑套組 國立臺灣大學醫學院附設醫院 106/01/06 115200.0
    HLA-B27定型試劑套組 國立臺灣大學醫學院附設醫院 105/05/18 115200.0
    HLA-B27定型試劑套組 國立臺灣大學醫學院附設醫院 103/07/09 890112.0
    HLA定序分型試劑套組(附儀器) 國立臺灣大學醫學院附設醫院 103/01/06
    HLA-B27定型試劑套組 國立臺灣大學醫學院附設醫院 102/09/18 550000.0
    裁判書查詢
  • Others
    2007, 2008, 2013
  • Change deposit
    2008
  • Compensation for damage
    2007, 2008
  • Revocation of Arbitration Judgment
    2007
  • Others
    2007, 2010, 2011
  • Return deposit
    2013
  • Stop execution
    2007
  • Compensation for damage
    2010
  • Return security deposit
    2006
  • Retrial for damage compensation
    2011
  • Petition filed for public summons
    2016
  • Revocation of Arbitration Judgment
    2008, 2010
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。